Jump to content

Blisibimod

From Wikipedia, the free encyclopedia
Blisibimod
Clinical data
Other namesA-623
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC2836H4376N756O858S26
Molar mass63624.20g·mol−1
☒NcheckY(what is this?)(verify)

Blisibimod(also known asA-623,formerlyAMG 623) is a selective antagonist ofB-cell activating factor(BAFF, also known as B-lymphocyte stimulator or BLyS), being developed byAnthera Pharmaceuticalsas a treatment forsystemic lupus erythematosus.[1]It is currently under active investigation in clinical trials.[2]

Mechanism of action[edit]

Blisibimod is afusion proteinconsisting of four BAFFbinding domainsfused to theN-terminusof thefragment crystallizable region(Fc) of a humanantibody.[1]

BAFF is involved inB-cellsurvival, activation, and differentiation.[3]Elevated levels of BAFF have been associated with several B-cell mediatedautoimmune diseases,including systemic lupus erythematosus,[4][5][6]lupus nephritis,[7]rheumatoid arthritis,[5][6]multiple sclerosis,[8]Sjögren syndrome,[9]Graves' disease,[10]andHashimoto's thyroiditis.[10]Blisibimod binds to BAFF andinhibitsinteraction with BAFFreceptors,thus decreasing B-cell survival and proliferation throughout the body.[1][3]Improvements in disease activity have been observed in patients with systemic lupus erythematosus[11]and rheumatoid arthritis[12]following treatment with BAFF inhibitors in clinical trials.

Development[edit]

Blisibimod was initially developed byAmgen,withPhase Itrials demonstrating comparable safety between the blisibimod andplacebotreatments.[1]It was subsequently acquired by Anthera Pharmaceuticals,[13]who in 2010 initiated a globalPhase IIstudy called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus.[2][14]The PEARL-SC study, completed in April 2012, yielded data that has been published.[15]Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for systemic lupus erythematosus, and a Phase 2 study, BRIGHT-SC, forIgA nephropathy.

References[edit]

  1. ^abcd"A-623: BAFF Peptibody for the Treatment of Lupus".Anthera Pharmaceuticals, Inc. Archived fromthe originalon 2011-09-02.Retrieved2011-07-08.
  2. ^ab"Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)"(Press release). Anthera Pharmaceuticals, Inc. 29 July 2010. Archived fromthe originalon 3 June 2011.Retrieved15 July2011.
  3. ^abBrowning JL (July 2006). "B cells move to centre stage: novel opportunities for autoimmune disease treatment".Nature Reviews. Drug Discovery.5(7): 564–576.doi:10.1038/nrd2085.PMID16816838.S2CID9159761.
  4. ^Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. (August 2008). "Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus".Arthritis and Rheumatism.58(8): 2453–2459.doi:10.1002/art.23678.hdl:2027.42/60900.PMID18668552.
  5. ^abCheema GS, Roschke V, Hilbert DM, Stohl W (June 2001)."Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases".Arthritis and Rheumatism.44(6): 1313–1319.doi:10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S.PMID11407690.
  6. ^abZhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. (January 2001)."Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus".Journal of Immunology.166(1): 6–10.doi:10.4049/jimmunol.166.1.6.PMID11123269.
  7. ^Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, et al. (January 2011)."Intrarenal production of B-cell survival factors in human lupus nephritis".Modern Pathology.24(1): 98–107.doi:10.1038/modpathol.2010.184.PMID20890272.S2CID11795623.
  8. ^Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. (January 2005)."BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma".The Journal of Experimental Medicine.201(2): 195–200.doi:10.1084/jem.20041674.PMC2212784.PMID15642740.
  9. ^Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, et al. (2008)."Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma".The Open Rheumatology Journal.2:38–43.doi:10.2174/1874312900802010038.PMC2577948.PMID19088870.
  10. ^abFabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al. (January 2010). "BLyS and April serum levels in patients with autoimmune thyroid diseases".Autoimmunity Reviews.9(3): 165–169.doi:10.1016/j.autrev.2009.07.005.PMID19647102.
  11. ^Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial".Lancet.377(9767): 721–731.doi:10.1016/S0140-6736(10)61354-2.PMID21296403.S2CID28952240.
  12. ^Genovese M, Bojin S, Biagini M, Mociran E, Cristei D, Georgescu L, Sloan-Lancaster J (June 2010)."Effects on B cells, safety, and efficacy of LY2127399, a novel anti-BAFF MAB, in patients with active rheumatoid arthritis".Annals of the Rheumatic Diseases.69(Suppl3): 69. Archived fromthe originalon 2011-10-02.Retrieved2011-07-15.
  13. ^"Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases"(Press release). Anthera Pharmaceuticals, Inc. 2008-01-08. Archived fromthe originalon 2012-03-27.Retrieved2011-07-15.
  14. ^Clinical trial numberNCT01162681for "PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus" atClinicalTrials.gov
  15. ^Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, et al. (September 2015). "A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study".Annals of the Rheumatic Diseases.74(9): 1667–1675.doi:10.1136/annrheumdis-2013-205144.PMID24748629.S2CID23122293.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Blisibimod&oldid=1189100366"